STOCK TITAN

Dyadic International (DYAI) Stock News

DYAI NASDAQ

Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.

Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.

Rhea-AI Summary

Dyadic International (NASDAQ: DYAI) reported third-quarter 2026 revenue of $449,101 as it recorded its first direct commercial protein sales. Revenue fell 61.4% year over year as grant activity declined and several collaboration projects had ended. Net loss narrowed to $1,357,041, or $0.04 per share, from $1,976,012, or $0.06 per share, helped by lower expenses and a non-cash warrant valuation gain.

Cash, restricted cash and investment-grade securities, including accrued interest, totaled $6,046,083 at September 30, versus $8,587,289 at year-end. Initial product sales were not material, and customer evaluations took longer than anticipated. Dyadic expects a $225,000 chymosin milestone payment and revenue recognition in the fourth quarter. Partner commercialization expanded, while comparative animal studies of C1-produced antibodies began in October, with results anticipated in the first quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.60%
Tags
-
Rhea-AI Summary

Dyadic International (DYAI) announced that Gates Medical Research Institute initiated animal studies of its C1-produced RSV and malaria antibodies on October 20, 2026. The studies compare RSM01 for respiratory syncytial virus (RSV) and MAM01 for malaria with versions produced using mammalian cells (CHO). Four groups of mice will assess pharmacokinetics, or how the antibodies move through the body. Results are expected in the first quarter of 2027.

The studies follow independent binding evaluations of both antibodies and neutralization testing of RSM01. Under its Gates Foundation-funded program, Dyadic achieved development-stage yields of approximately 12.1 g/L for RSM01 and 13.2 g/L for MAM01 in seven-day fermentation runs. Positive animal results could support further development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
none
-
Rhea-AI Summary

Dyadic International (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, announced a collaboration with BRIG BIO and Strive Nutrition to develop precision-fermented bovine alpha-lactalbumin.

The protein is intended for potential use in Strive’s FREEMILK platform and other nutrition products. Dyadic and BRIG BIO will optimize production, while Strive will evaluate samples for formulation and application testing. The parties target initial commercial availability of more than 10 metric tonnes after completing the self-affirmed GRAS process for food-ingredient safety, currently targeted for early 2028. Their longer-term production target is more than 200 metric tonnes annually. Commercialization depends on successful development, scale-up, regulatory readiness, quality qualification and definitive commercial agreements. A commercial supply agreement remains to be negotiated after successful evaluation and satisfaction of regulatory and quality requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
partnership
Rhea-AI Summary

Dyadic International (DYAI) will report third-quarter 2026 financial results and host a corporate update conference call on November 12, 2026.

The results cover the quarter ended September 30, 2026. The call begins at 5:00 p.m. Eastern Time. A webcast archive will be available within 24 hours after the live event and accessible through the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
conferences earnings date
-
Rhea-AI Summary

Dyadic International (NASDAQ: DYAI) entered into definitive agreements with an institutional investor for a registered direct offering of Common Stock and a concurrent private placement of warrants, expected to generate aggregate gross proceeds of approximately $2.9 million.

The company will sell 3,625,000 Common shares at $0.795 per share and issue Common Warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, with each Warrant priced at $0.005. Closing is expected on or about August 14, 2026, subject to customary conditions. Dyadic plans to use net proceeds, along with existing cash and investment-grade securities, for general corporate purposes and working capital. Aegis Capital is acting as exclusive placement agent. The stock offering is made under an effective Form S-3 shelf registration, while the warrants are offered via a private placement to accredited investors, with related resale registration rights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.49%
Tags
private placement offering
-
Rhea-AI Summary

Dyadic Applied BioSolutions (NASDAQ: DYAI) reported Q2 2026 revenue of $961,138, essentially flat year over year, as lower research and development and milestone revenue were offset by higher CEPI and Gates Foundation grant revenue. Cash, cash equivalents, restricted cash and investment-grade securities totaled $4.8 million at June 30, 2026, down from $8.6 million at year-end 2025.

Cost of revenue rose 60.4% to $984,165, while R&D expenses fell 47.2% and G&A expenses increased 17.6%. Loss from operations widened to $2.1 million and net loss to $2.1 million, or $(0.06) per share. Dyadic highlighted advancing commercial shipments, new dairy-protein and cultivated-meat collaborations, and progress in Gates Foundation-, CEPI- and NIAID-supported antibody and vaccine programs using its C1 platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.19%
Tags
Rhea-AI Summary

Dyadic (Nasdaq: DYAI) announced a new development and commercial license agreement with a European biotechnology company to expand its non-animal, precision-fermented dairy protein pipeline. The collaboration targets additional dairy proteins intended for a broad range of food and nutrition applications.

The agreement aligns with Dyadic's strategy to generate recurring revenue through development partnerships, licensing and commercial participation. According to Dyadic, it is eligible for development and commercial payments, licensing-related revenues and other economic participation tied to successful commercialization.

The program builds on Dyadic's existing Dapibus™-enabled initiatives, including commercial recombinant bovine chymosin with Inzymes ApS and development of bovine alpha-lactalbumin with BRIG BIO, reinforcing Dapibus™ as a scalable precision fermentation platform for commercial dairy proteins and enzymes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
-
Rhea-AI Summary

Dyadic (Nasdaq: DYAI) plans to report its Q2 2026 financial results and host a corporate update conference call on Wednesday, August 12, 2026, at 5:00 p.m. Eastern Time. Investors can join via toll-free and international dial-in numbers or a live webcast, with a replay available on Dyadic's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences earnings date
-
Rhea-AI Summary

Dyadic (Nasdaq: DYAI) reported that, in approximately 15 days after receiving plasmids, it developed stable pools of C1 cell lines and manufactured and initially purified two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens. The C1-produced antigens have been delivered to Fondazione Biotecnopolo di Siena and Scripps Research for preclinical evaluation in support of a potential non-mRNA Bundibugyo ebolavirus vaccine candidate.

According to Dyadic, this rapid turnaround highlights the C1 platform’s potential to accelerate development of vaccines, monoclonal antibodies and other biologics. The company notes C1’s scalability, high antibody titers exceeding 12 g/L in seven days, and the completed receipt of a $3.1 million Gates Foundation grant supporting monoclonal antibody programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
Rhea-AI Summary

Dyadic (Nasdaq: DYAI) announced that Nasdaq has confirmed the company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b), and its common stock will continue to be listed and traded on The Nasdaq Capital Market.

According to Dyadic, resolving the continued listing matter provides greater stability as it focuses on executing its business strategy, including developing and commercializing its own products, expanding adoption of its C1 and Dapibus™ protein production platforms, advancing strategic collaborations and pursuing long-term shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none

FAQ

What is the current stock price of Dyadic International (DYAI)?

Dyadic International (DYAI) last closed at $0.2870.

What is the market cap of Dyadic International (DYAI)?

The market cap of Dyadic International (DYAI) is approximately $11.5M.